Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019...
November 12 2019 - 06:55AM
Interpace (IDXG) announced today that it will report its third
quarter 2019 financial results on Wednesday, November 13, 2019 at
4:30 p.m. ET. Interpace will host a conference call and webcast to
discuss the Company’s financial results and provide a general
business update.
|
Purpose: To update the market on
Interpace’s Third Quarter 2019 financial results |
|
Date and Time: Wednesday, November 13,
2019 at 4:30 p.m. ET |
|
Dial-in Number (Domestic): (877)
407-0312 |
|
Dial-in Number (International): +1 (201)
389-0899 |
|
Confirmation Number: 13695822
Webcast Access:
https://webcasts.eqs.com/interpacedia20191113/en |
All listeners should confirm they are dialing in
for the Interpace conference call with the operator who will
promptly place them into the call. A webcast replay will be
available on the company’s website (www.interpacediagnostics.com)
approximately two hours following completion of the call and will
be archived on the company’s website for 90 days.
About Interpace, Inc.
Interpace is a leader in enabling personalized
medicine, offering specialized services along the therapeutic value
chain from early diagnosis and prognostic planning to targeted
therapeutic applications.
Interpace’s Diagnostic Business is a fully
integrated commercial and bioinformatics business unit that
provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has four
commercialized molecular tests and one test in a clinical
evaluation process (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT®
for the diagnosis of thyroid cancer from thyroid nodules utilizing
a next generation sequencing assay; ThyraMIR® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX® that differentiates lung
cancer of primary vs. metastatic origin. In addition, BarreGEN® for
Barrett’s Esophagus, is currently in a clinical evaluation program
whereby we gather information from physicians using BarreGEN® to
assist us in positioning the product for full launch, partnering
and potentially supporting reimbursement with payers.
Interpace’s Biopharma Business is a market
leader in providing pharmacogenomics testing, genotyping, and
biorepository services to the pharmaceutical and biotech
industries. The Biopharma Business also advances personalized
medicine by partnering with pharmaceutical, academic, and
technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs with the goals
of delivering safer, more effective drugs to market more quickly,
and improving patient care.
For more information, please visit Interpace’s website at
www.interpacediagnostics.com.
Forward-looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10Q. Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Company undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.
CONTACTS:Investor Relations - Edison
GroupJoseph Green(646) 653-7030jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2023 to Mar 2024